Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | Monooxygenase, putative | 0.0213 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0045 | 0.1185 | 0.0939 |
Mycobacterium ulcerans | hypothetical protein | 0.0213 | 1 | 1 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0213 | 1 | 0.5 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0213 | 1 | 0.5 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0213 | 1 | 0.5 |
Mycobacterium ulcerans | oxidoreductase GMC-type | 0.0213 | 1 | 1 |
Trypanosoma brucei | kynurenine 3-monooxygenase, putative | 0.0213 | 1 | 1 |
Mycobacterium ulcerans | oxidoreductase | 0.0213 | 1 | 1 |
Plasmodium vivax | hypothetical protein, conserved | 0.0213 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0213 | 1 | 1 |
Plasmodium vivax | FAD-dependent monooxygenase, putative | 0.0213 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0213 | 1 | 1 |
Mycobacterium leprae | possibleputative FAD-linked oxidoreductase | 0.0213 | 1 | 0.5 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0213 | 1 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 2-polyprenyl-6-methoxyphenol 4-hydroxylase | 0.0213 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0045 | 0.1185 | 0.0939 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.004 | 0.0914 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0045 | 0.1185 | 0.0939 |
Schistosoma mansoni | hypothetical protein | 0.0213 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0045 | 0.1185 | 1 |
Leishmania major | p450 reductase, putative | 0.0045 | 0.1185 | 0.0299 |
Giardia lamblia | Hypothetical protein | 0.004 | 0.0914 | 0.5 |
Mycobacterium ulcerans | FAD-linked oxidoreductase | 0.0213 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0045 | 0.1185 | 0.0939 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0045 | 0.1185 | 0.1185 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0045 | 0.1185 | 0.0299 |
Echinococcus multilocularis | ubiquinone biosynthesis monooxygenase COQ6 | 0.0213 | 1 | 1 |
Brugia malayi | flavodoxin family protein | 0.0045 | 0.1185 | 1 |
Toxoplasma gondii | FAD binding domain-containing protein | 0.0213 | 1 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0213 | 1 | 1 |
Mycobacterium ulcerans | FAD-dependent oxidoreductase | 0.0213 | 1 | 1 |
Echinococcus multilocularis | protein MICAL 3 | 0.0213 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0028 | 0.0272 | 0.0272 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0045 | 0.1185 | 0.0299 |
Loa Loa (eye worm) | hypothetical protein | 0.0213 | 1 | 1 |
Plasmodium falciparum | FAD-dependent monooxygenase, putative | 0.0213 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0213 | 1 | 1 |
Schistosoma mansoni | monoxygenase | 0.0213 | 1 | 1 |
Toxoplasma gondii | FAD binding domain-containing protein | 0.0213 | 1 | 0.5 |
Echinococcus granulosus | ubiquinone biosynthesis monooxygenase COQ6 | 0.0213 | 1 | 1 |
Mycobacterium ulcerans | oxidoreductase | 0.0213 | 1 | 1 |
Echinococcus granulosus | protein MICAL 3 | 0.0213 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0045 | 0.1185 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0045 | 0.1185 | 0.0939 |
Mycobacterium ulcerans | membrane-associated oxidoreductase | 0.0213 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0213 | 1 | 1 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0213 | 1 | 0.5 |
Trypanosoma cruzi | Monooxygenase, putative | 0.0213 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0045 | 0.1185 | 0.0939 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC (functional) | > 32 ug ml-1 | In vitro antibacterial activity against methicillin resistant Staphylococcus aureus ATCC 33591 (S. a. 019) | ChEMBL. | 12190317 |
MIC (functional) | > 32 ug ml-1 | In vitro antibacterial activity against Staphylococcus aureus ATCC 49951 (S. a. 213) | ChEMBL. | 12190317 |
MIC (functional) | > 32 ug ml-1 | In vitro antibacterial activity against Staphylococcus aureus ATCC 29213 (S. a. 035) | ChEMBL. | 12190317 |
MIC (functional) | > 32 ug ml-1 | In vitro antibacterial activity against Enterococcus faecalis ATCC 29212 (E. f. 034) vancomycin sensitive | ChEMBL. | 12190317 |
MIC (functional) | > 32 ug ml-1 | In vitro antibacterial activity against Enterococcus faecalis NCTC 12201 (E. f. 153) vancomycin resistant | ChEMBL. | 12190317 |
MIC (functional) | > 32 ug ml-1 | In vivo antibacterial activity against Enterococcus faecium ATCC 12202 (E.fm 154) vancomycin resistant | ChEMBL. | 12190317 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.